Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cervarix Adjuvant Could Provide Longer Cancer Immune Response, GSK Says

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK's AS04 adjuvant demonstrates increased immune memory compared to aluminum adjuvants, such as the one used in Merck's Gardasil HPV vaccine.

You may also be interested in...



GSK Receives “Complete Response” Letter For Cervarix BLA

Drug maker will respond to FDA “as soon as possible” to answer outstanding questions related to the HPV vaccine.

GSK Receives “Complete Response” Letter For Cervarix BLA

Drug maker will respond to FDA “as soon as possible” to answer outstanding questions related to the HPV vaccine.

FDA Denies Priority Review For GlaxoSmithKline’s HPV Vaccine Cervarix

Decision could give Merck’s Gardasil an extra four months without HPV vaccine competition.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel